Nothing Special   »   [go: up one dir, main page]

DE60316323D1 - Feste pharmazeutische formulierungen mit telmisartan - Google Patents

Feste pharmazeutische formulierungen mit telmisartan

Info

Publication number
DE60316323D1
DE60316323D1 DE60316323T DE60316323T DE60316323D1 DE 60316323 D1 DE60316323 D1 DE 60316323D1 DE 60316323 T DE60316323 T DE 60316323T DE 60316323 T DE60316323 T DE 60316323T DE 60316323 D1 DE60316323 D1 DE 60316323D1
Authority
DE
Germany
Prior art keywords
telmisartan
pharmaceutical formulations
solid pharmaceutical
solid
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60316323T
Other languages
English (en)
Other versions
DE60316323T2 (de
Inventor
Manabu Nakatani
Toshimitsu Ohki
Sawada Takeshi
Kenzo Toyoshima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31984063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60316323(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of DE60316323D1 publication Critical patent/DE60316323D1/de
Application granted granted Critical
Publication of DE60316323T2 publication Critical patent/DE60316323T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60316323T 2002-09-24 2003-09-18 Feste pharmazeutische formulierungen mit telmisartan Expired - Lifetime DE60316323T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10244681A DE10244681A1 (de) 2002-09-24 2002-09-24 Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
DE10244681 2002-09-24
PCT/EP2003/010382 WO2004028505A1 (en) 2002-09-24 2003-09-18 Solid pharmaceutical formulations comprising telmisartan

Publications (2)

Publication Number Publication Date
DE60316323D1 true DE60316323D1 (de) 2007-10-25
DE60316323T2 DE60316323T2 (de) 2008-01-17

Family

ID=31984063

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10244681A Withdrawn DE10244681A1 (de) 2002-09-24 2002-09-24 Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
DE60316323T Expired - Lifetime DE60316323T2 (de) 2002-09-24 2003-09-18 Feste pharmazeutische formulierungen mit telmisartan

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE10244681A Withdrawn DE10244681A1 (de) 2002-09-24 2002-09-24 Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung

Country Status (32)

Country Link
EP (1) EP1545467B1 (de)
JP (1) JP4606166B2 (de)
KR (2) KR101188650B1 (de)
CN (2) CN1684665A (de)
AR (2) AR041370A1 (de)
AT (1) ATE372765T1 (de)
AU (1) AU2003270220B2 (de)
BR (1) BR0314687A (de)
CA (1) CA2499878C (de)
CY (1) CY1107075T1 (de)
DE (2) DE10244681A1 (de)
DK (1) DK1545467T3 (de)
EA (1) EA009237B1 (de)
EC (1) ECSP055688A (de)
ES (1) ES2294312T3 (de)
HR (1) HRP20050280B1 (de)
IL (1) IL167610A (de)
ME (1) MEP46008A (de)
MX (1) MXPA05003039A (de)
MY (1) MY136524A (de)
NO (1) NO334449B1 (de)
NZ (1) NZ539522A (de)
PE (1) PE20040418A1 (de)
PL (1) PL206396B1 (de)
PT (1) PT1545467E (de)
RS (1) RS51756B (de)
SI (1) SI1545467T1 (de)
TW (1) TWI319319B (de)
UA (1) UA81781C2 (de)
UY (1) UY27995A1 (de)
WO (1) WO2004028505A1 (de)
ZA (1) ZA200501087B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319450A1 (de) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
ES2277199T3 (es) * 2004-04-15 2007-07-01 Helm Ag Procedimiento para la preparacion de adsorbatos de valsartan pulverulentos de flujo libre.
US20060078615A1 (en) * 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin
EP1699765A1 (de) 2004-10-15 2006-09-13 Teva Pharmaceutical Industries Ltd Verfahren zur herstellung von telmisartan
EP1807400A2 (de) * 2004-11-03 2007-07-18 Teva Pharmaceutical Industries, Inc. Amorphe und polymorphe formen von telmisartan-natrium
JP5134963B2 (ja) * 2004-11-05 2013-01-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング テルミサルタンとアムロジピンを含む二層錠剤
US9149433B2 (en) * 2004-11-30 2015-10-06 Basf Corporation Method for formation of micro-prilled polymers
CN100370984C (zh) * 2005-03-11 2008-02-27 浙江泰利森药业有限公司 替米沙坦分散片及其制备方法
WO2007061415A1 (en) * 2005-11-22 2007-05-31 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of telmisartan
US8637078B2 (en) * 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
ES2523729T3 (es) 2006-06-16 2014-12-01 Lek Pharmaceuticals D.D. Composición farmacéutica que comprende hidroclorotiazida y telmisartán
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
EP1908469A1 (de) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II Rezeptor Antagonisten zur Behandlung von systemischen Krankheiten bei Katzen
EP1970053A1 (de) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmazeutische Zusammensetzung
FR2918277B1 (fr) * 2007-07-06 2012-10-05 Coretecholding Nouveau procede de production de formes pharmaceutiques seches hydrodispersibles et les compositions hydrodispersibles ainsi obtenues
WO2009135646A2 (en) 2008-05-05 2009-11-12 Farmaprojects, Sa Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale
CZ301070B6 (cs) * 2008-07-31 2009-10-29 Zentiva, A. S. Telmisartan tablety
US9169238B2 (en) 2008-07-31 2015-10-27 Takeda Pharmaceutical Company Limited Solid pharmaceutical composition
AU2010251194B2 (en) * 2009-05-20 2016-02-25 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical oral telmisartan solution
PL2443094T3 (pl) 2009-06-19 2013-08-30 Krka Tovarna Zdravil D D Novo Mesto Sposób wytwarzania telmisartanu
EP2448576A2 (de) 2009-07-02 2012-05-09 Mahmut Bilgic Löslichkeitsverstärkende pharmazeutische zusammensetzung
EP2448575A2 (de) 2009-07-02 2012-05-09 Bilgic Mahmut Pharmazeutische zusammensetzung mit verbesserter löslichkeit und haltbarkeit
JP2011136908A (ja) * 2009-12-25 2011-07-14 Kyowa Yakuhin Kogyo Kk アンギオテンシンｉｉ受容体拮抗剤を含む固形製剤および固形製剤におけるアンギオテンシンｉｉ受容体拮抗剤の保存安定性向上方法
CA2706292A1 (en) * 2010-05-28 2011-11-28 Pharmascience Inc. A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
WO2011161123A2 (en) 2010-06-21 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
TWI564008B (zh) * 2010-09-30 2017-01-01 鹽野義製藥股份有限公司 難溶性藥物之溶解性改善製劑
CN102133189B (zh) * 2011-03-18 2012-06-27 海南美兰史克制药有限公司 替米沙坦脂质体固体制剂
JP6081376B2 (ja) * 2011-12-28 2017-02-15 ニプロ株式会社 アンギオテンシンｉｉ拮抗作用を有する化合物を含有する固形医薬組成物
EP2612658A1 (de) 2012-01-05 2013-07-10 Laboratorios Lesvi, S.L. Pharmazeutische Zusammensetzungen von 4'-[(1,4'-Dimethyl-2'-propyl-[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carbonsäure und deren 6-Chlor-3,4-dihydro-2H-1,2,4-benzothiadiazin-7-sulfonamid-1,1-dioxid
WO2014068507A1 (en) 2012-11-02 2014-05-08 Abbott Healthcare Pvt. Ltd. Solid oral pharmaceutical compositions of telmisartan, essentially free of surfactants
EP2952196A4 (de) * 2013-01-31 2016-08-03 Sawai Seiyaku Kk Mehrschichtige tablette mit telmisartan und hydrochlorothiazid
JP6218664B2 (ja) * 2013-04-04 2017-10-25 沢井製薬株式会社 テルミサルタン含有錠剤
JP6344678B2 (ja) * 2013-09-27 2018-06-20 キョーリンリメディオ株式会社 テルミサルタン含有製剤及びその製造方法
CN104688696B (zh) * 2013-12-04 2017-12-19 长春海悦药业股份有限公司 一种含有坎地沙坦酯的药物组合物
JP6428340B2 (ja) * 2014-05-23 2018-11-28 ニプロ株式会社 テルミサルタンを含む医薬組成物の造粒方法
JP6440294B2 (ja) * 2014-07-01 2018-12-19 大原薬品工業株式会社 テルミサルタン含有フィルムコーティング錠剤
EP2979691A1 (de) 2014-07-30 2016-02-03 Boehringer Ingelheim International GmbH Zerfallende Tablette zur oralen Einnahme
JP6565930B2 (ja) * 2014-11-19 2019-08-28 ニプロ株式会社 口腔内崩壊錠の製造方法
JP5827428B1 (ja) * 2015-01-15 2015-12-02 日新製薬株式会社 テルミサルタン含有錠剤
CN104739833A (zh) * 2015-02-16 2015-07-01 江苏欧信医药化工有限公司 含替米沙坦和瑞舒伐他汀钙的复方双层片剂及其制备方法
JP5956034B1 (ja) * 2015-07-27 2016-07-20 エルメッド エーザイ株式会社 テルミサルタン含有医薬組成物
CN107982232A (zh) * 2018-01-29 2018-05-04 威特(湖南)药业有限公司 替米沙坦片及其制备方法
CN109350604B (zh) * 2018-11-20 2020-04-21 广州迈达康医药科技有限公司 一种替米沙坦肠溶片及其制备方法
CN110934848B (zh) * 2019-12-20 2022-02-15 江西杏林白马药业股份有限公司 一种替米沙坦胶囊及其制备方法
CN111265488B (zh) * 2020-03-18 2021-11-12 重庆康刻尔制药股份有限公司 一种替米沙坦片及其制备方法
CN112870174A (zh) * 2021-02-08 2021-06-01 天方药业有限公司 一种替米沙坦片剂的制备方法
CN115245497A (zh) * 2021-04-26 2022-10-28 武汉伯睿科医药科技有限公司 替米沙坦胶囊及其制备工艺
WO2024240633A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
WO2000027396A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Medicaments based on combinations of lacidipine and telmisartan or of physiological derivatives thereof
FR2787330A1 (fr) * 1998-12-18 2000-06-23 Sanofi Sa Composition pharmaceutique contenant, en association, un antagoniste des recepteurs at1 de l'angiotensine ii et un immunosuppresseur pour la prevention ou le traitement des complications vasculaires du rejet de greffe
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
JP2001139461A (ja) * 1999-11-10 2001-05-22 Ohta Pharmaceut Co Ltd 速崩壊性錠剤
JP2001278812A (ja) * 2000-03-27 2001-10-10 Kyoto Pharmaceutical Industries Ltd 錠剤用崩壊剤及びこれを用いた錠剤
DK2260833T3 (da) * 2002-01-16 2013-01-07 Boehringer Ingelheim Pharma Tolags farmaceutisk tablet omfattende telmisartan og et diuretika

Also Published As

Publication number Publication date
KR101188650B1 (ko) 2012-10-09
EA009237B1 (ru) 2007-12-28
HRP20050280A2 (en) 2006-05-31
PE20040418A1 (es) 2004-08-16
KR101107508B1 (ko) 2012-01-31
SI1545467T1 (sl) 2008-02-29
KR20110122882A (ko) 2011-11-11
EP1545467A1 (de) 2005-06-29
DK1545467T3 (da) 2007-11-05
AU2003270220B2 (en) 2009-06-04
CA2499878A1 (en) 2004-04-08
RS51756B (sr) 2011-12-31
AR087239A2 (es) 2014-03-12
MXPA05003039A (es) 2005-05-27
MY136524A (en) 2008-10-31
ES2294312T3 (es) 2008-04-01
NO20050688L (no) 2005-03-23
NZ539522A (en) 2006-10-27
KR20050053690A (ko) 2005-06-08
ZA200501087B (en) 2006-11-29
HRP20050280B1 (hr) 2014-01-03
RS20050239A (en) 2007-06-04
DE60316323T2 (de) 2008-01-17
UA81781C2 (uk) 2008-02-11
PT1545467E (pt) 2007-11-27
TW200418463A (en) 2004-10-01
IL167610A (en) 2009-02-11
WO2004028505A1 (en) 2004-04-08
CA2499878C (en) 2012-03-13
NO334449B1 (no) 2014-03-03
JP4606166B2 (ja) 2011-01-05
JP2006502194A (ja) 2006-01-19
PL206396B1 (pl) 2010-08-31
AU2003270220A1 (en) 2004-04-19
DE10244681A1 (de) 2004-04-08
ECSP055688A (es) 2005-05-30
UY27995A1 (es) 2004-05-31
TWI319319B (en) 2010-01-11
AR041370A1 (es) 2005-05-11
BR0314687A (pt) 2005-08-02
PL374347A1 (en) 2005-10-17
EA200500405A1 (ru) 2005-10-27
CN101785769A (zh) 2010-07-28
EP1545467B1 (de) 2007-09-12
CY1107075T1 (el) 2012-10-24
ATE372765T1 (de) 2007-09-15
MEP46008A (en) 2011-02-10
CN1684665A (zh) 2005-10-19

Similar Documents

Publication Publication Date Title
DE60316323D1 (de) Feste pharmazeutische formulierungen mit telmisartan
DE602004025950D1 (de) Pharmazeutische formulierung mit lanthanum-verbindungen
PT1501534E (pt) Formulacoes farmaceuticas
DE602005012107D1 (de) Pharmazeutische formulierungen mit einem antibioti
DE60209145D1 (de) Pharmazeutische formulierungen mit platinderivaten
ATE336264T1 (de) Dispergierbare pharmazeutische zusammensetzungen
DE602004016444D1 (de) Azithromycin enthaltende pharmazeutische Zusammensetzungen mit verringerten Nebenwirkungen
DK1545662T3 (da) Lægemiddelindgivelsessystem
DE60316552D1 (de) Tablette mit hohem wirkstoffgehalt
DK3384931T3 (da) Superfin formoterolformulering
ATE380544T1 (de) Umhüllte feste darreichungsform
DE60118008D1 (de) Pharmazeutische zusammensetzungen mit amlodipinmaleat
IS7571A (is) Ný lífeðlisfræðilega virk efni
DE60332393D1 (de) Flüssige pharmazeutische zusammensetzung mit pyridonderivaten
DE602004016967D1 (de) Flüssige pharmazeutische palonosetronformulierungen
DE60308372D1 (de) Dosierungsverabreichungsvorrichtung
DE60312049D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
IS7564A (is) Lyfjablanda með breytta losun
DK1596870T4 (da) Højdosis-ibandronatformulering
DE60305728D1 (de) PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT VERLuNGERTER FREISETZUNG
ATE415949T1 (de) Pharmazeutische formulierung mit levothyroxin- natrium
DE602004024220D1 (de) Pharmazeutische modafinil-zusammensetzungen mit modifizierter freisetzung
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DE60336999D1 (de) Melatonin enthaltende pharmazeutische formulierung
DE60310526D1 (de) Ivabradin enthaltende pharmazeutische zusammensetzung mit oraler dispersion

Legal Events

Date Code Title Description
8364 No opposition during term of opposition